We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Genome-wide Association Study

This study has been withdrawn prior to enrollment.
(Registration poor)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01498757
First Posted: December 23, 2011
Last Update Posted: December 29, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jeeyun Lee, Samsung Medical Center
December 21, 2011
December 23, 2011
December 29, 2015
January 2012
June 2012   (Final data collection date for primary outcome measure)
Biomarkers predictive [ Time Frame: 24months ]
Biomarkers predictive of clinical response to Taxane or 5-fluorouracil or platinum based chemotherapy.
Same as current
Complete list of historical versions of study NCT01498757 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Genome-wide Association Study
Genome-wide Association Study to Predict Treatment Response for Chemotherapy in Esophageal Squamous Cell Carcinoma
To explore biomarkers predictive of clinical response to Taxane/5-FU/platinum based chemotherapy in esophageal squamous cell carcinoma. To identify negative predictive markers to 5-FU/platinum/Taxane. To elucidate signal transduction pathway attributable to 5-FU/platinum/Taxane resistance. To analyze correlation between the quantity of circulating tumor cells and circulating endothelial cell precursors and treatment response to Taxane/5-FU/platinum based chemotherapy.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Esophageal squamous cell carcinoma Patients treated with Taxane/5-FU/platinum based chemotherapy.
Esophageal Squamous Cell Carcinoma.
Not Provided
Patients treated with Taxane/5-FU/platinum based chemo.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
Not Provided
June 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histological confirmed esophageal squamous cell carcinoma
  • Patients treated with Taxane or 5-FU or platinum based chemotherapy.
  • provision of a signed written informed consent.

Exclusion Criteria:

  • patients not signed written informed consent.
  • patient unacceptable for study in the judgement of the investigator.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT01498757
2011-05-076
No
Not Provided
Not Provided
Jeeyun Lee, Samsung Medical Center
Samsung Medical Center
Not Provided
Not Provided
Samsung Medical Center
December 2015